Clinical and Biological Implications of Tumor Heterogeneity (2023)

Linthicum, MD US
March 3, 2023 to March 4, 2023

Johns Hopkins Greenberg Bladder Cancer Institute and American Urological Association Translational Research Collaboration

Clinical and Biological Implications of Tumor Heterogeneity (2023) will be held in-person, March 3-4, 2023 at AUA Headquarters in Linthicum, MD.

The sixth annual translational research meeting co-sponsored by the American Urological Association and the Johns Hopkins Greenberg Bladder Cancer Institute will be a two-day, in-person symposium focused on the “Clinical and Biological implications of Tumor Heterogeneity”.

Large genomics projects such as The Cancer Genome Atlas (TCGA) and UROMOL bladder cancer projects provided “snapshot” descriptions of bladder cancer based on bulk tumor sequencing data.  New single-cell and spatial profiling platforms and longitudinal measurements of primary tumors, recurrences, and metastases are revealing tumor heterogeneity that presents challenges for biomarker development and precision medicine.  The purpose of this workshop is to bring together clinical and research thought leaders to review the current state of the science and develop new methods for accommodating tumor heterogeneity in biomarker development and the clinical management of bladder cancer in patients.  The workshop will focus on 4 major research areas that appear to be significantly impacted by tumor heterogeneity – molecular subtypes, DNA-based clonal evolution, the tumor immune landscape, and bladder cancer histologic variants.

Note the deadline for registration is Thursday, March 2, 2023 at 12:OO pm EST. 

PROGRAM PLANNING COMMITTEE

  • David McConkey, PhD (Chair) - Johns Hopkins University Greenberg Bladder Cancer Institute
  • Aria, Olumi, MD - Beth Israel Deaconess and Harvard Medical School
  • Diane Zipursky Quale, JD - Bladder Cancer Advocacy Network
  • Andrea Apolo, MD - National Cancer Institute
  • Arlene Siefker-Radtke, MD - University of Texas MD Anderson Cancer Center
  • Rosalyn Adam, PhD - Boston Children's Hospital
  • Philip Beachy, PhD - Stanford Medicine
  • Jason Efstathiou, MD, DPhil - Harvard Medical School, Massachusetts General Hospital
  • Phuoc Tran, MD, PhD - Johns Hopkins 
  • Peter Black, MD - Vancouver Prostate Centre, University of British Columbia
  • Yair Lotan, MD - UT Southwestern Medical Center
  • Seth Lerner, MD - Baylor College of Medicine
  • Joshua Meeks, MD, PhD - Northwestern Medicine
  • James McKierman, MD - Columbia University
  • Eugene Pietzak, MD -  Memorial Sloan Kettering Cancer Center
  • Rick Bangs, MBA - SWOG Cancer Research Network

COURSE REGISTRATION FEES

Membership CategoryPrice

MD/PhD Member

$235

MD/PhD Non-Member

$290

Member Medical Student, Resident, Fellow

$160

Non-Member Medical Student, Resident, Fellow

$175

Employees of Industry

$475

Invited Faculty/Speakers

$0

 

ACKNOWLEDGEMENTS

This educational activity is supported by independent educational grants from:

  • Merck & Co., Inc

 

Target Audience

  • Urologists
  • Research scientists
  • Clinical and research faculty
  • Clinical and postdoctoral fellows
  • Residents
  • Medical and graduate students
  • Medical professionals employed by industry

Learning Objectives

At the conclusion of this meeting, participants will be able to:

  1. Describe the extent to which tumor heterogeneity influences the major RNA- and DNA-based biomarkers that are being developed for bladder preservation, selection of adjuvant therapy, and other personalized clinical management approaches.
  2.  Discuss the biological basis for tumor heterogeneity and gaps in current knowledge about these mechanisms.
  3.  Explain patient perspectives on the use of biomarkers for guiding clinical management of bladder cancer.
  4.   Describe strategies to overcome the challenges presented by tumor heterogeneity.
Course summary
Available credit: 
  • 8.75 AMA PRA Category 1 Credit™
  • 8.75 Non-Physician Participation
Course opens: 
01/01/2023
Course expires: 
03/04/2026
Event starts: 
03/03/2023 - 2:30pm EST
Event ends: 
03/04/2023 - 2:50pm EST
Price:
$235.00
Rating: 
0

*agenda updates will be posted as they become available.
All times are listed in EST.

2023 AUA-JHU GBCI Bladder Cancer Research Symposium
Clinical and Biological implications of tumor Heterogeneity

Friday, March 3 - Saturday, March 4, 2023
AUA Headquarters, Linthicum, Maryland, USA

FRIDAY, March 3, 2023

Time

Running Time

Title

Speaker

2:00 PM

30 min

Arrival, Registration, Coffee and Refreshments

n/a

2:30 PM

10 min

Welcome, Opening Remarks, and Goal Setting

David McConkey, PhD

Director, Johns Hopkins Greenberg Bladder Cancer Institute

10 min

Welcome Address from AUA Research Council

Dr. Steven Kaplan, AUA Research Council Chair

10 min

Welcome Address from Office of Research

Dr. Christine Riordan, AUA Office of Research Director

3:00 PM

1 hour

Patient Panel: Patient Perspectives and Why They Matter to Research

Moderator: Stephanie Chisolm, PhD

Director of Education and Research

Bladder Cancer Advocacy Network

Patient: TBA

Patient: TBA

Patient: TBA

Patient: TBA

Patient: TBA

15 min

Discussion, Q&A

Moderator: Stephanie Chisolm, PhD

4:15 PM

15 min

Break

n/a

4:30 PM

6 min

SESSION 1: Molecular heterogeneity and plasticity in the molecular subtypes of bladder cancer

Intro: David McConkey, PhD

14 min

SUBTYP: a molecular subtypes-based neoadjuvant trial

Seth Lerner, Baylor

14 min

Molecular subtypes and response to chemotherapy: the CoXEN trial

Woonyoung Choi, JHU

14 min

Molecular subtypes and response to chemotherapy: the VESPER trial

Clarice, Groneveld

14 min

Chromatin-modifying enzymes and subtype plasticity

Michael Shen, Columbia                                                            

14 min

Lineage plasticity in Urothelial Cancer

David DeGraff, Penn State                                                                               

14 min

Molecular subtypes: pathology considerations

Joshua Warrick, Penn State                                                          

30 min

Discussion, Q&A

Moderator: David McConkey, PhD

6:30 PM

2 hr

Networking Reception and Dinner

n/a

8:30 PM

 

Adjourn

n/a

Saturday, March 4, 2023

Time

Running Time

Title

Speaker Name

8:00 AM

30 min

Breakfast and Morning Registration

n/a

8:30 AM

6 min

SESSION 2: Clonal Evolution

Intro: Hikmat Al-Ahmadie, MSKCC

14 min

Circulating tumor DNA and clonal evolution

Lars Dyrskjot, Aarhus (Denmark)

14 min

Deciphering urothelial cancer evolution through mutational and structural variant signatures

Bishoy Faltas, Weill Cornell

14 min

Clonal evolution as visualized in rapid autopsy

Andrew Hsieh, FHCRC

14 min

Urine tumor DNA and clonal evolution

Roger Li, Moffit Cancer Center

14 min

ctDNA to assess genomic heterogeneity

Gillian Vandekerkhove, (UBC)

14 min

Clinical implications of tumor evolution in urothelial carcinoma

Eugene Pietzak MSKCC

15 min

Discussion, Q&A

Moderator: Hikmat Al-Ahmadie, MSKCC

10:15 AM

15 min

BREAK

 n/a

10:30 AM

5 min

SESSION 3: Heterogeneity in the tumor immune landscape

Intro: David McConkey, PhD

11 min

Heterogeneity in the responses to systemic immunotherapy

Andrea Apolo, NCI

11 min

Determinants of response to BCG

Amir Horowitz, Mt Sinai/NYC

11 min

Profiling the tumor immune landscape

William Kim, UNC

11 min

Whole body imaging of tumor immune heterogeneity

Elisabeth De Vries

11 min

Lineage plasticity and urothelial intrinsic inflammatory signaling

David Degraff, Penn State

15 min

Discussion, Q&A

Moderator: David McConkey, PhD

11:45 PM

1hr

Lunch Keynote: Defining the Actionable Cancer Genome

David Solit, Memorial Sloan Kettering Cancer Center

15 min

Discussion, Q&A

Moderator: David McConkey, PhD

1:00 PM

4 min

SESSION 4: Variant histology: Origin and Implications

Intro: David Degraff, Penn State

14 min

Clinical significance of variants and mixed tumors

Donna Hansel, MD Anderson

14 min

Variants and response to systemic therapies

 

Jonathan Rosenberg, MSKCC

14 min

New insights into urothelial carcinoma with squamous differentiation

Hikmat Al-Ahmadie, MSKCC

14 min

Mixed small cell bladder cancer

Andres Matoso, JHU                                                                           

15 min

Discussion, Q&A

Moderator: David Degraff, Penn State

2:15 PM

5 min

Final Meeting Discussion

David McConkey, PhD

Director, Johns Hopkins Greenberg Bladder Cancer Institute

2:30 PM

 

Closing Remarks/Adjourn 

 

 

AUA Headquarters
1000 Corporate Boulevard
Linthicum, MD 21090
United States

Clinical and Biological Implications of Tumor Heterogeneity (2023) will be held in-person on March 3-4, 2023 at the AUA Headquarters. 


Hotel Information

The AUA has reserved a block of rooms at the Hilton Garden Inn BWI Airport, 1516 Aero Drive, Linthicum Heights, MD 21090.

  • To hold a reservation, a major credit card number must be provided.
  • The room block is for Friday, March 3, 2023 only. (If you require additional nights, please contact Shira Rubin at srubin@auanet.org to assist you.)
  • $104 single/double occupancy.

Make your reservation online or call 410-691-0500 and reference the AUA/JHU Bladder Cancer Meeting when making your reservation to receive the special group rate.

Click Here to Reserve Your Room

Cut-off Date: Friday, February 10, 2023. Once the AUA group block is full, which may be prior to the cut-off date, the AUA is unable to guarantee rooms at this rate or at this hotel.

Check-in: 3pm
Check-out: 12pm
 

Travel

Please contact Shira Rubin, srubin@auanet.org for hotel and travel information.

Faculty and Planner Disclosures 

Financial Disclosures will be added prior to the event.

AUA Staff have nothing to disclose.

All relevant financial disclosures have been mitigated.

AUA ACCREDITATION INFORMATION

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 8.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic 

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

AUA PARTICIPANT INFORMATION & POLICIES

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Consent to Use of Photographic Images: Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Available Credit

  • 8.75 AMA PRA Category 1 Credit™
  • 8.75 Non-Physician Participation

Price

Price:
$235.00
Please login or register to take this course.

Note the deadline for registration is Thursday, March 2, 2023 at 12:OO pm EST. 

Registration Fees

Membership CategoryPrice

MD/PhD Member

$235

MD/PhD Non-Member

$290

Member Medical Student, Resident, Fellow

$160

Non-Member Medical Student, Resident, Fellow

$175

Employees of Industry

$475

Invited Faculty/Speakers

$0

Required Hardware/software

Laptop or tablet with Wi-Fi capabilities
Charger